Dr. Kimberly L. Blackwell on a Promising HER2 Breast Cancer Treatment

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants their experiences treating patients with triple-negative breast cancer.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, discussed the currently approved JAK inhibitors used to treat patients with myelofibrosis, and exciting movements in the field.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.

In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.